Latest Period
Q1 2026
Security Snapshot
Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) Institutional Ownership
CUSIP: Y95308105
13F Institutional Holders and Ownership History from Q4 2015 to Q1 2026
Institutions Reporting
226
Shares (Excl. Options)
172,478,533
Price
$7.25
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares, no par value
- Symbol
- WVE on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 172,478,533
- Total 13F value
- $1,247,355,027
- Portfolio coverage rank
- 0.01%
- Share change
- -10,620,214
- Value change
- -$203,869,620
- Number of holders
- 226
- Shares outstanding
- 188,679,245
- SEC-reported price per share
- $6.42
- Insider filing price
- $6.42
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- WVE - Wave Life Sciences Ltd. - Ordinary Shares, no par value is tracked under CUSIP Y95308105.
- 226 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 218 to 226 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $3,108,291,748 to $1,247,355,027.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 226 institutions filings for Q1 2026.
Security key
Y95308105
Latest holder period
Q1 2026
13F holders
226
13D/G owners
5
CIK / CUSIP context first
Open Q1 2026 holders
WVE full holder history
Wave Life Sciences Ltd. SEC filings
Wave Life Sciences Ltd. company facts
Wave Life Sciences Ltd. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP Y95308105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
WVE
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 17% | -2.2% | $248,138,341 | 34,225,506 | 0% | RA Capital Management, L.P. | 15 Apr 2026 | |
| BlackRock, Inc. | 6.1% | $63,555,507 | 9,360,163 | BlackRock, Inc. | 31 Dec 2024 | |||
| MAVERICK CAPITAL LTD | 5.4% | $56,093,833 | 8,261,242 | Maverick Capital, Ltd. | 31 Dec 2024 | |||
| FMR LLC | 2.8% | -63% | $37,284,027 | -$70,566,627 | 5,192,761 | -65% | FMR LLC | 31 Mar 2026 |
| Adage Capital Management, L.P. | 0.53% | -96% | $7,180,000 | -$63,083,918 | 1,000,000 | -90% | Adage Capital Management, L.P. | 31 Mar 2026 |
As of 31 Mar 2026, 226 institutional investors reported holding 172,478,533 shares of Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE). This represents 91% of the company’s total 188,679,245 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
72%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 14% | 26,975,505 | +48% | 2.1% | $195,572,411 |
| GSK plc | 9.7% | 18,245,691 | 0% | 22% | $132,281,260 |
| BlackRock, Inc. | 7.5% | 14,117,412 | +12% | 0% | $102,351,241 |
| MAVERICK CAPITAL LTD | 5.4% | 10,161,399 | +9.5% | 0.86% | $73,670,143 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.6% | 8,704,550 | +18% | 0.01% | $63,109,000 |
| Driehaus Capital Management LLC | 2.9% | 5,431,021 | -17% | 0.29% | $39,374,902 |
| FEDERATED HERMES, INC. | 2.8% | 5,317,457 | +12% | 0.06% | $38,551,563 |
| FMR LLC | 2.8% | 5,192,761 | -66% | 0% | $37,647,520 |
| 683 Capital Management, LLC | 2.6% | 4,900,000 | +22% | 3.3% | $35,525,000 |
| PRIMECAP MANAGEMENT CO/CA/ | 2.6% | 4,832,952 | +18% | 0.03% | $35,038,906 |
| M28 Capital Management LP | 2.4% | 4,588,284 | -19% | 62% | $33,265,059 |
| STATE STREET CORP | 1.9% | 3,674,033 | +23% | 0% | $26,636,739 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.9% | 3,579,099 | +13% | 0% | $25,953,676 |
| Siren, L.L.C. | 1.3% | 2,450,000 | 0% | 0.49% | $17,762,500 |
| CITADEL ADVISORS LLC | 1.2% | 2,202,856 | +179% | 0.01% | $15,970,706 |
| TWO SIGMA INVESTMENTS, LP | 1% | 1,878,115 | +151% | 0.01% | $13,616,334 |
| Pfizer Inc | 0.99% | 1,875,000 | 0% | 5% | $11,934,375 |
| First Light Asset Management, LLC | 0.98% | 1,843,968 | -0.53% | 1.2% | $13,368,768 |
| MARSHALL WACE, LLP | 0.95% | 1,789,882 | 0.01% | $12,976,646 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.85% | 1,611,853 | 0% | 0% | $11,685,934 |
| Squarepoint Ops LLC | 0.78% | 1,462,390 | +66% | 0.02% | $10,602,328 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 0.76% | 1,441,059 | +43% | 0.01% | $9,539,811 |
| Affinity Asset Advisors, LLC | 0.74% | 1,401,727 | -48% | 0.6% | $10,162,521 |
| GOLDMAN SACHS GROUP INC | 0.73% | 1,383,590 | -52% | 0% | $10,031,028 |
| MORGAN STANLEY | 0.72% | 1,361,001 | +232% | 0% | $9,867,260 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
42
Latest
Q1 2026
Rows shown
1-25 of 42
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 172,478,533 | $1,247,355,027 | -$203,869,620 | $7.25 | 226 |
| 2025 Q4 | 182,758,755 | $3,108,291,748 | +$421,681,651 | $17.00 | 218 |
| 2025 Q3 | 143,680,189 | $1,051,640,675 | +$37,184,597 | $7.32 | 187 |
| 2025 Q2 | 138,939,054 | $903,136,388 | +$46,387,682 | $6.50 | 174 |
| 2025 Q1 | 131,293,097 | $1,061,209,645 | +$20,316,471 | $8.08 | 192 |
| 2024 Q4 | 128,616,529 | $1,591,015,441 | +$86,595,360 | $12.37 | 181 |
| 2024 Q3 | 120,246,621 | $986,101,781 | +$176,011,863 | $8.20 | 160 |
| 2024 Q2 | 95,071,148 | $474,405,111 | +$9,854,270 | $4.99 | 143 |
| 2024 Q1 | 92,759,614 | $572,308,103 | +$4,033,614 | $6.17 | 131 |
| 2023 Q4 | 92,528,153 | $468,029,084 | +$93,144,169 | $5.05 | 115 |
| 2023 Q3 | 72,598,087 | $417,436,128 | +$3,006,886 | $5.75 | 85 |
| 2023 Q2 | 72,147,137 | $262,614,478 | +$6,429,830 | $3.64 | 80 |
| 2023 Q1 | 70,086,593 | $303,466,627 | +$3,780,454 | $4.33 | 72 |
| 2022 Q4 | 68,108,089 | $476,736,473 | +$7,420,705 | $7.00 | 74 |
| 2022 Q3 | 67,256,615 | $242,816,542 | -$1,613,831 | $3.61 | 58 |
| 2022 Q2 | 67,784,074 | $220,297,785 | +$69,127,143 | $3.25 | 56 |
| 2022 Q1 | 47,551,964 | $95,097,268 | -$1,035,989 | $2.00 | 77 |
| 2021 Q4 | 47,284,486 | $148,479,513 | +$13,347,500 | $3.14 | 87 |
| 2021 Q3 | 37,428,616 | $183,549,240 | +$443,975 | $4.90 | 84 |
| 2021 Q2 | 37,041,603 | $246,689,021 | -$5,849,970 | $6.66 | 82 |
| 2021 Q1 | 38,281,847 | $214,782,368 | +$1,495,724 | $5.61 | 97 |
| 2020 Q4 | 36,092,793 | $284,070,815 | -$9,567,182 | $7.87 | 102 |
| 2020 Q3 | 37,117,728 | $315,928,313 | +$59,335,508 | $8.49 | 106 |
| 2020 Q2 | 29,422,263 | $306,287,769 | -$6,711,423 | $10.41 | 89 |
| 2020 Q1 | 30,100,828 | $282,072,986 | +$9,439,494 | $9.37 | 76 |